Hints and tips:
...mid-level hire who had come with the Merrill Lynch team, would establish himself as the top banker to emerging biotech companies seeking to sell themselves, most notably the landmark sale of Kite Pharma to Gilead...
...Sofosbuvir was invented by Pharmasset, a company later acquired by Gilead, according to a World Health Organization document. It is patent-protected in the US but not in Iran and other countries....
...The US drugmaker Gilead has hired Daniel O’Day as its new chief executive, the FT reported. O’Day joins from Swiss rival Roche....
...Gilead’s $11.2bn purchase of Pharmasset, a hepatitis C biotech, in 2012, brought with it one of the most lucrative drug franchises....
...Other bestselling treatments approved this year in China are Gilead’s hepatitis treatment Epclusa, approved in May, and Merck’s vaccine for human papillomavirus, Gardasil 9, given the go-ahead in April after...
...Gilead partisans note that it had bought Pharmasset in 2012 for a similar sum to Kite....
...That's exactly what happened six years ago after Gilead acquired Pharmasset for $11bn....
...For Gilead, the takeover of Kite culminates a long search for a blockbuster deal, the largest since it acquired Pharmasset for $11bn six years ago....
...John Milligan, chief executive of Gilead, says there are “some similarities” between the acquisition of Kite and the company’s last big deal: the $11.2bn takeover of Pharmasset in 2012, which brought with...
...Gilead’s $11bn purchase of Pharmasset in 2011 was risky, but turned out to be one of the best deals ever....
...In 2011, when Gilead announced that it would pay $11bn for Pharmasset and its unproven Hepatitis C drug Sofosbuvir, there were gripes , and the shares fell 10 per cent....
...takeover of Pharmasset, a developer of drugs for hepatitis C....
...The company is also facing a challenge in HIV, the mainstay of its business before it acquired Pharmasset, and the rights to its hepatitis C drugs, for $11bn in 2012....
...Gilead Gilead is often held up as the biggest success story of biotech....
...So too are new remedies such as Gilead’s Harvoni hepatitis C drug, which retails at the startling sticker price of $84,000 for a 12 week regimen....
...Amgen, founded in 1980, is one of the four cornerstone groups of the US biotech sector, along with Celgene, Gilead and Biogen, and is credited with developing some of the first successful “biologic” drugs...
...Roughly $273bn has been wiped off the valuations of constituents of the index since its peak, including $10bn plus haircuts to Valeant, Celgene, Gilead Sciences, Amgen and Biogen Idec — more than the valuations...
...The top quartile on this measure — a cohort including Netflix, Amazon, Gilead and Biogen — has returned 6 per cent on average; returns on the rest of the stocks in the index are, on average, negative....
...Gilead, the biggest of the pack, spent $11bn on Pharmasset in 2011, gaining control of a hepatitis C medicine that would go on to be one of the biggest drug launches of all time....
...In 2011, drugs group Gilead spent $11bn to buy Pharmasset, which was developing treatments for hepatitis C, but could only promise investors that the deal would be “accretive in 2015 and beyond”....
...Gilead, which markets Sovaldi, may recoup annually the $11bn it paid in 2011 for Pharmasset, the company which developed the drug....
...Companies have been encouraged to take calculated risks on development-stage drugs by successes such as Gilead Science’s $11bn acquisition of Pharmasset in 2011 — before the approval of the Sovaldi hepatitis...
...Gilead’s $11bn acquisition of Pharmasset, in 2011, brought along an HCV treatment, sofosbuvir....
...This was considerably less than half the sum set by Gilead after it bought Pharmasset for $11bn in 2011. Gilead and its allies have strongly defended Sovaldi’s price....
...In 2011 Gilead acquired Pharmasset for control of the hepatitis C drug Sovaldi. Gilead paid $11bn – a huge premium – and shares fell....
International Edition